Clinical trial · Interventional
Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort
Interactions Between Tumor, Tumor Microenvironment and Immune System in Digestive Cancers : Impact on Survival and Response to Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies. Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored. Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers. Method: Retrospective and prospective monocentric cohort study
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Tumor | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Immune System and Related Disorders | — | UNRESOLVED | — |
| Pancreas Tumor | Pancreatic Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tumor samples | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- digestive cancers
- description
- Colorectal and pancreatobiliary cancers
- interventionNames
- Biological: Tumor samples
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- observation from first cancer treatment date until date of death or 10 years follow up if patient alive
- description
- Overall survival (OS): vital status (alive/deceased)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma * Cytologically or histologically proven adenocarcinoma, regardless of stage and treatment * Age ≥ 18 years old * Diagnosed from 2015 onwards * Signed Consent * Affiliation to a social security scheme (including CMU (Universal health coverage)) Exclusion Criteria: * Patient under guardianship, curatorship or safeguarding of justice * Pregnant or breastfeeding woman * Any medical, psychological or social situation that could prevent compliance with the protocol according to the investigator's assessment. * Refusal to participate in the study * Patient on AME (state medical assistance) * Persons deprived of liberty by a judicial or administrative decision * Persons under psychiatric care
References
Publications (0)
Data not yet available